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Abstract	  
Primary	  hyperoxaluria	  Type	  1	  is	  a	  rare	  autosomal	  recessive	  inborn	  error	  of	  glyoxylate	  metabolism,	  caused	  
by	  a	  deficiency	  of	  the	  liver-­‐specific	  enzyme	  alanine:glyoxylate	  aminotransferase.	  The	  disorder	  results	  in	  
overproduction	  and	  excessive	  urinary	  excretion	  of	  oxalate,	  causing	  recurrent	  urolithiasis	  and	  
nephrocalcinosis.	  As	  glomerular	  filtration	  rate	  declines	  due	  to	  progressive	  renal	  involvement,	  oxalate	  
accumulates	  leading	  to	  systemic	  oxalosis.	  The	  diagnosis	  is	  based	  on	  clinical	  and	  sonographic	  findings,	  urine	  
oxalate	  assessment,	  enzymology	  and/or	  DNA	  analysis.	  Early	  initiation	  of	  conservative	  treatment	  (high	  fluid	  
intake,	  pyridoxine,	  inhibitors	  of	  calcium	  oxalate	  crystallization)	  aims	  at	  maintaining	  renal	  function.	  In	  




combined	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The	  term	  ‘primary	  hyperoxaluria’	  (PH)	  encompasses	  an	  indeterminate	  number	  of	  rare	  autosomal	  recessive	  
calcium	  oxalate	  kidney	  stone	  diseases,	  of	  which	  three	  have	  been	  described	  at	  the	  molecular	  level.	  PH1	  is	  
caused	  by	  mutations	  in	  the	  AGXT	  gene,	  which	  lead	  to	  dysfunction	  of	  the	  vitamin	  B6-­‐dependent	  liver-­‐
specific	  peroxisomal	  enzyme	  alanine:glyoxylate	  aminotransferase	  (AGT)	  [1,	  2].	  PH2	  arises	  from	  mutations	  in	  
the	  GRHPR	  gene	  and	  subsequent	  dysfunction	  of	  the	  enzyme	  glyoxylate/hydroxypyruvate	  reductase	  
(GRHPR)	  [3–5].	  PH3	  is	  caused	  by	  mutations	  in	  the	  HOGA1	  gene,	  which	  is	  thought	  to	  encode	  the	  
mitochondrial	  enzyme	  4-­‐hydroxy-­‐2-­‐oxoglutarate	  aldolase	  [6].	  
This	  paper	  focuses	  on	  PH	  Type	  1	  (PH1,	  OMIM	  259900),	  the	  commonest	  form	  of	  PH.	  The	  clinical	  
presentation	  ranges	  from	  asymptomatic	  through	  to	  isolated	  or	  recurrent	  renal	  stones,	  nephrocalcinosis	  and	  
renal	  impairment.	  The	  heterogeneous	  presentation	  leads	  to	  a	  diagnostic	  challenge	  and	  therefore,	  specific	  
biochemical	  and	  genetic	  assessment	  is	  required	  to	  confirm	  a	  diagnosis	  of	  PH1	  and	  to	  institute	  appropriate	  
treatment.	  
	  
Materials	  and	  methods	  
PH1	  is	  a	  very	  rare	  inherited	  disease	  with	  a	  limited	  access	  to	  recommendations	  for	  diagnosis	  and	  
management,	  due	  to	  the	  lack	  of	  randomized	  clinical	  trials	  and	  meta-­‐analyses.	  An	  expert	  group	  (OxalEurope)	  
has	  therefore	  been	  established	  to	  provide	  diagnostic	  and	  therapeutic	  recommendations	  for	  patients	  with	  
PH.	  Experts	  were	  selected	  on	  both	  their	  individual	  commitment	  and	  their	  peer-­‐reviewed	  publication	  
activity	  in	  this	  field.	  Number	  of	  PubMed	  papers	  were	  (MeSH:	  hyperoxaluria,	  October	  2011):	  Acquaviva	  3,	  
Cochat	  34,	  Danpure	  64,	  Daudon	  25,	  De	  Marchi	  3,	  Fargue	  8,	  Groothof	  6,	  Harambat	  7,	  Hoppe	  43,	  Hulton	  7,	  
Jamieson	  10,	  Kemper	  20,	  Mandrile	  3,	  Marangella	  45,	  Picca	  1,	  Rumsby	  41,	  Salido	  15,	  Straub	  2	  and	  van	  
Woerden	  6.	  Due	  to	  the	  rarity	  of	  the	  disease	  and	  the	  lack	  of	  evidence	  coming	  from	  randomized	  clinical	  trials,	  
recommendations	  are	  based	  on	  ungraded	  statements.	  
	  
Demography	  
PH1	  has	  an	  estimated	  prevalence	  ranging	  from	  one	  to	  three	  per	  million	  and	  an	  estimated	  incidence	  rate	  of	  
∼1:100 000	  live	  births	  per	  year	  in	  Europe	  [7–9].	  Higher	  rates	  are	  reported	  in	  isolated	  populations	  [10].	  PH	  
accounts	  for	  ∼1%	  of	  paediatric	  end-­‐stage	  renal	  disease	  (ESRD)	  in	  registries	  from	  Europe,	  USA	  and	  Japan	  
[11–13].	  In	  contrast,	  PH	  is	  more	  prevalent	  in	  countries	  where	  consanguineous	  marriages	  are	  common:	  
∼10%	  of	  Kuwaiti	  and	  ∼13%	  of	  Tunisian	  children	  with	  ESRD	  have	  been	  reported	  to	  have	  PH	  [14,	  15].	  
	  
Presentation	  
PH1	  may	  present	  at	  any	  age.	  The	  presentation	  varies	  from	  infantile	  nephrocalcinosis	  and	  failure	  to	  thrive	  as	  
a	  result	  of	  renal	  impairment	  to	  recurrent	  or	  only	  occasional	  stone	  formation	  [16].	  Although	  patients	  with	  
presentation	  in	  adulthood	  often	  have	  a	  history	  of	  only	  sporadic	  stone	  disease,	  over	  50%	  of	  these	  patients	  
present	  with	  ESRD	  at	  the	  time	  of	  diagnosis	  [9,	  17].	  Some	  patients	  may	  be	  identified	  as	  pre-­‐symptomatic	  
subjects	  with	  a	  family	  history	  of	  PH1	  [16].	  As	  a	  result	  of	  kidney	  injury,	  glomerular	  filtration	  rate	  (GFR)	  
always	  declines	  leading	  to	  chronic	  kidney	  disease	  (CKD)	  and	  ultimately	  to	  ESRD	  and	  further	  systemic	  
involvement	  (named	  ‘oxalosis’).	  
	  
Clinical	  and	  radiological	  assessment	  
(1)	   We	  recommend	  considering	  a	  diagnosis	  of	  PH	  in	  any	  child	  with	  a	  first	  kidney	  stone	  and	  in	  adults	  with	  
recurrent	  stone	  disease.	  
	  (2)	   We	  recommend	  considering	  a	  diagnosis	  of	  PH	  in	  any	  subject	  with	  nephrocalcinosis	  particularly	  when	  
associated	  with	  decreased	  GFR.	  
(3)	   We	  recommend	  searching	  for	  PH	  in	  the	  presence	  of	  oxalate	  crystals	  (calcium	  oxalate	  monohydrate)	  in	  
any	  biological	  fluid	  or	  tissue.	  
(4)	   We	  recommend	  screening	  relatives	  of	  index	  cases.	  
(5)	   We	  do	  not	  recommend	  screening	  in	  the	  general	  population.	  
Patients	  should	  undergo	  metabolic	  screening	  for	  PH1	  at	  presentation	  of	  a	  first	  kidney	  stone	  (in	  a	  child)	  or	  
recurrent	  or	  familial	  stone	  disease	  (at	  any	  age)	  or	  if	  nephrocalcinosis	  is	  detected.	  Stone	  analysis	  may	  reveal	  
characteristic	  morphology	  and	  contain	  >95%	  calcium	  oxalate	  (CaOx)	  monohydrate	  (whewellite)	  often	  
presenting	  with	  a	  particular	  morphology	  [18].	  PH1	  should	  be	  considered	  in	  any	  patient	  with	  renal	  failure	  of	  
unknown	  cause,	  particularly	  in	  the	  presence	  of	  nephrocalcinosis	  or	  severe	  stone	  burden.	  
Preliminary	  PH1	  diagnostic	  workup	  should	  include	  24-­‐h	  urine	  collection	  for	  oxalate,	  creatinine	  and	  
glycolate;	  plasma	  oxalate	  (POx)	  when	  GFR	  is	  <60	  mL/min/1.73m2.	  
More	  specific	  investigations	  are	  covered	  in	  the	  biochemical	  and	  genetic	  sections	  below.	  
Ultrasonography	  (US)	  of	  the	  kidneys	  may	  elucidate	  stones	  and/or	  medullary	  or	  diffuse	  nephrocalcinosis.	  
Patients	  with	  ESRD	  from	  PH	  may	  have	  diffuse	  cortical	  nephrocalcinosis	  which	  can	  be	  hard	  to	  distinguish	  
from	  the	  common	  picture	  of	  an	  ‘end-­‐stage	  kidney’	  by	  US	  (Table	  1).	  
PH	  patients	  with	  a	  GFR	  <60	  mL/min/1.73m2	  should	  undergo	  regular	  measurement	  of	  POx	  and	  monitoring	  
of	  eye	  involvement	  by	  fundoscopy	  (Table	  1).	  In	  addition,	  those	  with	  a	  GFR	  <30	  mL/min/1.73m2	  should	  
undergo	  assessment	  of	  cardiac	  involvement	  by	  ECG—echocardiography,	  and	  bone	  by	  X-­‐ray	  as	  appropriate.	  
US	  and	  computed	  tomography	  scan	  of	  heart	  and	  visceral	  organs	  can	  assist	  in	  evaluating	  the	  level	  of	  
calcification	  in	  patients	  with	  systemic	  oxalosis.	  
	  
Biochemical	  and	  enzymological	  assessment	  
(1)	   We	  recommend	  measuring	  24-­‐h	  urine	  oxalate,	  creatinine	  and	  glycolate	  in	  any	  patient	  with	  a	  possible	  
diagnosis	  of	  PH1	  and	  preserved	  renal	  function	  as	  a	  first-­‐line	  evaluation.	  
(2)	   We	  recommend	  measuring	  plasma	  oxalate	  in	  CKD	  patients.	  
(3)	   We	  recommend	  measurement	  of	  AGT	  enzyme	  activity	  if	  genetic	  testing	  is	  inconclusive.	  
The	  usual	  biochemical	  indicator	  of	  PH1	  is	  a	  persistently	  and	  markedly	  elevated	  urine	  oxalate	  (UOx)	  
excretion	  >0.5	  mmol/1.73m2	  per	  day	  in	  the	  absence	  of	  secondary	  causes	  of	  hyperoxaluria.	  There	  is	  no	  clear	  
cut-­‐off	  for	  primary	  disease	  versus	  secondary	  hyperoxaluria:	  an	  excretion	  >0.7	  mmol/1.73m2	  per	  day	  is	  
more	  likely	  to	  have	  a	  metabolic	  cause	  but	  some	  secondary	  cases	  due	  to	  Crohn's	  disease,	  other	  chronic	  
intestinal	  disease,	  short	  bowel	  syndrome	  and	  pancreatic	  insufficiency	  secondary	  to	  cystic	  fibrosis	  [19,	  20]	  
can	  have	  grossly	  elevated	  (>1	  mmol/1.73m2	  per	  day)	  oxalate	  excretion.	  Values	  which	  fall	  between	  0.5	  and	  
0.7	  cannot	  exclude	  PH	  and	  a	  strong	  clinical	  suspicion	  e.g.	  recurrent	  stones,	  young	  age,	  heavy	  crystalluria	  
(>200	  calcium	  oxalate	  monohydrate	  crystals/mm3)	  should	  lead	  to	  more	  specific	  investigations.	  In	  children,	  
oxalate	  to	  creatinine	  ratio	  can	  be	  determined	  on	  random	  urine	  specimens,	  but	  ratios	  fall	  rapidly	  in	  early	  life	  
and	  are	  influenced	  by	  prematurity	  and	  nutrition;	  thus,	  interpretation	  requires	  an	  age-­‐related	  reference	  
range	  [21,	  22].	  Molar	  creatinine	  ratios	  from	  spot	  urine	  may	  give	  conflicting	  results	  so	  that	  confirmation	  of	  
hyperoxaluria	  from	  a	  24-­‐h	  urine	  collection	  related	  to	  body	  surface	  area	  is	  recommended	  at	  all	  ages.	  A	  
raised	  urine	  glycolate	  excretion	  is	  suggestive	  of	  PH1	  but	  has	  a	  low	  diagnostic	  sensitivity	  and	  specificity;	  
indeed,	  it	  is	  elevated	  in	  only	  two-­‐thirds	  of	  patients	  and	  can	  rise	  as	  a	  result	  of	  dietary	  intake.	  
POx	  is	  unhelpful	  for	  diagnosis	  if	  renal	  function	  is	  normal.	  POx	  will	  increase	  as	  GFR	  falls	  and	  there	  is	  no	  clear	  
cut-­‐off	  to	  distinguish	  patients	  with	  PH	  from	  those	  with	  renal	  failure	  from	  any	  other	  cause,	  although	  values	  
>100	  μmol/L	  are	  more	  likely	  to	  be	  due	  to	  PH.	  Plasma	  glycolate	  may	  also	  be	  helpful	  in	  some	  patients	  [23].	  
The	  presence	  of	  oxalate	  crystals	  in	  a	  renal	  biopsy	  brings	  further	  support	  for	  a	  metabolic	  disturbance	  as	  the	  
underlying	  cause.	  
The	  gold	  standard	  diagnostic	  test	  is	  the	  measurement	  of	  AGT	  catalytic	  and	  immunoreactivity	  in	  a	  liver	  
biopsy	  specimen	  [24],	  which	  has	  a	  sensitivity	  >95%;	  false	  negatives	  are	  possible,	  albeit	  rarely,	  in	  patients	  
with	  the	  p.Gly170Arg	  mutation	  [25]	  in	  which	  catalytic	  activity	  is	  preserved	  but	  the	  enzyme	  is	  non-­‐functional	  
in	  vivo	  due	  to	  intracellular	  mislocation.	  The	  wider	  availability	  of	  genetic	  testing	  has	  increased	  use	  of	  DNA	  
analysis	  for	  diagnosis	  although	  there	  are	  still	  some	  cases	  in	  whom	  no	  mutation	  is	  found	  in	  the	  AGXT	  gene;	  
AGT	  catalytic	  activity	  is	  therefore	  needed	  in	  these	  patients	  in	  order	  to	  completely	  exclude	  PH1.	  Additional	  
genetic	  analysis	  of	  the	  GRHPR	  and	  HOGA1	  genes	  can	  be	  performed	  to	  confirm/exclude	  PH2	  and	  PH3,	  which	  
may	  have	  a	  similar	  presentation.	  
Whenever	  the	  causative	  mutation(s)	  are	  known,	  DNA	  analysis	  is	  the	  method	  of	  choice	  for	  prenatal	  testing	  
and	  diagnosis	  in	  other	  family	  members.	  
	  
Genetic	  tests	  for	  mutations	  in	  the	  AGXT	  gene	  
(1)	   We	  recommend	  genetic	  testing	  in	  subjects	  with	  phenotypic	  characteristics	  of	  PH1.	  
(2)	   We	  recommend	  extending	  mutation	  analysis	  to	  siblings	  and	  parents.	  
(3)	   We	  recommend	  offering	  prenatal	  diagnosis	  using	  mutation	  analysis	  to	  parents	  of	  an	  affected	  child.	  
Over	  150	  different	  mutations	  have	  been	  found	  so	  far	  in	  the	  AGXT	  gene	  [26].	  Although	  most	  mutations	  are	  
restricted	  to	  individual	  families,	  some	  are	  found	  at	  high	  frequency	  e.g.	  p.Gly170Arg	  (also	  known	  as	  G170R)	  
found	  in	  ∼30%	  of	  mutant	  PH1	  alleles.	  Many	  PH1	  mutations,	  including	  p.Gly170Arg,	  segregate	  and	  
functionally	  interact	  with	  the	  common	  intragenic	  polymorphism	  Pro11Leu	  [27],	  which	  appears	  to	  increase	  
their	  pathogenicity.	  
Genomic	  DNA	  isolated	  from	  ethylenediaminetetraacetic	  acid	  blood	  is	  the	  sample	  of	  choice.	  Salivary	  DNA	  
and	  chorionic	  villus	  (for	  prenatal)	  are	  also	  suitable	  for	  diagnosis	  and	  carrier	  testing.	  All	  samples	  should	  be	  
accompanied	  by	  detailed	  clinical	  and	  laboratory	  data	  to	  support	  the	  appropriateness	  of	  the	  request	  as	  well	  
as	  documented	  consent	  for	  the	  analysis.	  
Targeted	  sequence	  analysis	  of	  Exons	  1,	  4	  and	  7	  of	  AGXT	  has	  been	  proposed	  for	  first-­‐line	  testing,	  with	  test	  
sensitivity	  of	  70%	  for	  a	  single	  mutation	  in	  a	  biopsy-­‐proven	  population	  [28].	  However,	  additional	  sequence	  
of	  the	  entire	  coding	  region	  and	  flanking	  intronic	  regions	  will	  be	  required	  in	  up	  to	  50%	  of	  patients	  and	  is	  
strongly	  recommended.	  While	  it	  is	  not	  advised	  to	  include	  polymorphic	  variants	  in	  reports,	  the	  presence	  of	  
the	  p.Pro11Leu	  (major/minor)	  variant	  is	  of	  significance	  and	  we	  recommend	  that	  this	  change	  is	  included	  in	  
the	  report.	  It	  is	  recommended	  to	  always	  extend	  the	  analysis	  to	  both	  parents	  to	  confirm	  the	  segregation	  of	  
any	  identified	  mutation(s).	  The	  results	  should	  be	  reported	  following	  recognized	  guidelines	  for	  
nomenclature	  (www.hgvs.org)	  and	  content	  (www.ssgm.ch).	  For	  novel	  mutations,	  the	  report	  should	  include	  
some	  indication	  of	  the	  likely	  pathogenicity.	  
For	  affected	  individuals	  and	  families	  in	  whom	  no	  mutation	  or	  only	  a	  single	  disease-­‐causing	  mutation	  is	  
identified,	  additional	  analyses	  may	  be	  indicated.	  Multiplex	  ligation-­‐dependent	  probe	  amplification	  analysis	  
can	  be	  used	  to	  search	  for	  gene	  deletions	  or	  duplications.	  No	  recommendation	  can	  yet	  be	  given	  on	  its	  
performance	  with	  AGXT	  due	  to	  little	  experience	  with	  the	  available	  kit.	  If	  no	  diagnosis	  is	  achieved,	  testing	  for	  
PH2	  and	  PH3	  should	  be	  considered,	  even	  if	  evidence	  is	  limited	  to	  few	  patients	  studied.	  In	  cases	  with	  a	  
strong	  suspicion	  but	  no	  mutation	  found	  in	  the	  three	  genes,	  a	  liver	  biopsy	  should	  be	  considered.	  
Linkage	  analysis	  with	  intragenic	  (e.g.	  the	  variable	  number	  tandem	  repeat	  in	  intron	  4)	  and	  extragenic	  
markers	  can	  be	  helpful	  particularly	  for	  prenatal	  diagnosis	  and	  family	  studies	  [29–31].	  The	  accuracy	  can	  be	  
as	  high	  as	  99%	  but	  depends	  on	  a	  correct	  clinical	  diagnosis	  of	  PH1	  in	  the	  affected	  relative(s)	  and	  on	  the	  
informativeness	  of	  genetic	  markers	  in	  the	  family.	  
Any	  report	  of	  genetic	  test	  should	  be	  given	  to	  the	  patients	  by	  a	  genetic	  counsellor	  or	  specialist/consultant	  
with	  a	  good	  knowledge	  of	  PH.	  However,	  prediction	  on	  the	  clinical	  course	  of	  the	  disease	  cannot	  be	  made	  on	  




(1)	   We	  recommend	  starting	  conservative	  therapy	  as	  soon	  as	  a	  diagnosis	  of	  PH1	  has	  been	  suggested.	  
a)	  We	  recommend	  a	  high	  fluid	  intake,	  at	  least	  3	  L/m2	  per	  24	  h.	  
b)	  We	  recommend	  using	  a	  nasogastric	  tube	  or	  gastrostomy	  feeding	  tube	  to	  guarantee	  adequate	  hydration,	  
mainly	  in	  infants.	  
c)	  We	  recommend	  administering	  vitamin	  B6	  (pyridoxine)	  in	  any	  patients	  with	  proven	  PH1,	  starting	  at	  a	  dose	  
of	  5	  mg/kg	  per	  day	  and	  not	  exceeding	  20	  mg/kg	  per	  day,	  aiming	  to	  decrease	  urine	  oxalate	  excretion	  by	  
<30%.	  
d)	  We	  recommend	  calcium	  oxalate	  crystallization	  inhibition	  by	  use	  of	  alkalization	  with	  oral	  potassium	  
citrate	  at	  a	  dose	  of	  0.10–0.15	  g/kg	  body	  weight	  per	  day	  (0.3–0.5	  mmol/kg)	  as	  long	  as	  GFR	  is	  preserved.	  
(2)	   We	  do	  not	  recommend	  special	  dietary	  interventions	  other	  than	  for	  other	  concurrent	  diseases	  in	  the	  
absence	  of	  CKD.	  
Conservative	  measures	  should	  be	  initiated,	  as	  soon	  as	  investigations	  are	  completed	  and	  while	  renal	  
function	  is	  maintained.	  Once	  ESRD	  is	  established,	  pyridoxine	  is	  the	  only	  specific	  treatment	  that	  should	  be	  
pursued.	  
The	  following	  measures	  apply	  to	  all	  types	  of	  PH	  with	  the	  exception	  of	  pyridoxine,	  which	  is	  specific	  to	  PH1.	  
High	  fluid	  intake	  
High	  fluid	  intake	  in	  stone	  formers	  has	  been	  proven	  to	  be	  effective	  in	  epidemiological	  and	  prospective	  
intervention	  studies	  [32].	  In	  PH,	  the	  recommended	  fluid	  intake	  is	  >3	  L/m2	  per	  day,	  distributed	  throughout	  
24	  h.	  In	  infants	  and	  small	  children,	  a	  feeding	  or	  gastrostomy	  tube	  is	  often	  required.	  Special	  care	  should	  be	  
taken	  in	  situations	  of	  fluid	  losses	  (diarrhoea,	  vomiting	  and	  fever)	  or	  limited	  oral	  hydration	  (surgery)	  and	  
intravenous	  (i.v.)	  fluid	  intake	  instituted	  if	  necessary.	  
Vitamin	  B6	  
Pyridoxal	  phosphate,	  one	  of	  the	  vitamin	  B6	  vitaminers,	  is	  a	  cofactor	  for	  AGT.	  Administration	  of	  pyridoxine	  
hydrochloride	  has	  been	  shown	  to	  be	  associated	  with	  a	  decrease	  in	  UOx	  in	  ∼30%	  of	  patients	  with	  PH	  [33,	  
34],	  but	  the	  metabolic	  basis	  of	  pyridoxine	  responsiveness	  is	  not	  clear.	  All	  PH1	  patients	  should	  be	  tested	  for	  
pyridoxine	  responsiveness,	  and	  if	  responsive,	  treated	  until	  liver	  transplantation	  is	  performed,	  even	  if	  
undergoing	  haemodialysis	  (HD).	  The	  recommended	  starting	  dose	  is	  5	  mg/kg	  per	  day,	  increasing	  by	  5	  mg/kg	  
steps	  to	  a	  maximum	  of	  20	  mg/kg	  per	  day	  [35].	  Responsiveness	  has	  been	  noted	  at	  doses	  inferior	  to	  5	  mg/kg	  
per	  day.	  Responsiveness	  is	  currently	  defined	  by	  a	  >30%	  decrease	  in	  UOx	  excretion	  after	  a	  test	  period	  of	  a	  
minimum	  of	  3	  months	  at	  maximum	  dose	  [36,	  37].	  Absorption	  of	  pyridoxine	  may	  vary	  between	  patients	  and	  
assessing	  plasma	  levels	  may	  be	  useful,	  although	  therapeutic	  levels	  are	  not	  clearly	  defined.	  Side	  effects	  are	  
rarely	  seen	  and	  sensory	  neurotoxicity	  is	  unusual.	  A	  subset	  of	  patients	  carrying	  one	  or	  two	  copies	  of	  
p.Gly170Arg	  or	  p.Phe152Ile	  mutation	  are	  more	  likely	  to	  respond	  to	  pharmacological	  doses	  of	  pyridoxine,	  
with	  other	  mutations	  possibly	  similarly	  responsive	  [38,	  39].	  
Alkalization	  of	  the	  urine	  
Alkalization	  of	  the	  urine	  with	  alkali	  citrate	  can	  reduce	  urinary	  CaOx	  saturation	  by	  forming	  complexes	  with	  
calcium	  thus	  decreasing	  stone	  growth	  or	  nephrocalcinosis	  [40].	  Potassium	  citrate	  at	  a	  dose	  of	  0.10–0.15	  
g/kg	  body	  weight	  per	  day	  (0.3–0.5	  mmol/kg)	  is	  recommended.	  It	  may	  be	  replaced	  by	  sodium	  citrate	  
appropriate	  to	  GFR	  and	  plasma	  potassium.	  
Other	  inhibitors	  of	  calcium	  oxalate	  crystallization	  
Other	  inhibitors	  of	  calcium	  oxalate	  crystallization	  such	  as	  pyrophosphate	  ions	  may	  decrease	  CaOx	  
crystallization	  although	  orthophosphate	  has	  never	  been	  evaluated	  independently	  of	  other	  treatments	  [41].	  
Moderate	  doses	  of	  phosphate	  20–30	  mg/kg	  per	  day	  may	  be	  administered.	  There	  is	  no	  evidence	  that	  
magnesium	  monotherapy	  can	  prevent	  stone	  formation	  [42,	  43].	  Despite	  the	  ability	  of	  Oxalobacter	  
formigenes	  to	  metabolize	  oxalate,	  there	  is	  as	  yet	  no	  evidence	  that	  probiotics	  can	  significantly	  decrease	  UOx	  
excretion	  in	  PH	  patients	  [44,	  45].	  
Diet	  
A	  restriction	  in	  oxalate	  intake	  is	  of	  limited	  use	  as	  the	  main	  source	  of	  oxalate	  is	  endogenous	  and	  intestinal	  
oxalate	  absorption	  is	  lower	  in	  PH	  patients	  compared	  to	  normal	  subjects	  [46];	  however,	  relying	  on	  
precautionary	  principle,	  some	  experts	  recommend	  avoiding	  oxalate-­‐rich	  foods	  in	  the	  diet.	  Calcium	  intake	  
should	  remain	  normal	  as	  oral	  calcium	  binds	  intestinal	  oxalate	  and	  dietary	  calcium	  restriction	  results	  in	  
higher	  oxalate	  intestinal	  absorption	  [47,	  48].	  Excessive	  intake	  of	  vitamin	  C	  and	  D	  is	  to	  be	  avoided.	  Careful	  
vitamin	  D	  supplementation	  in	  children	  is	  recommended.	  Ascorbic	  acid	  i.v.	  supplementation	  should	  be	  used	  
with	  caution	  in	  dialysis	  PH	  patients	  [49].	  
Monitoring	  
The	  monitoring	  of	  urinary	  pH,	  volume	  and	  oxalate	  excretion	  may	  be	  useful.	  When	  advanced	  CKD	  has	  been	  
reached,	  oxalosis	  bone	  involvement	  may	  be	  responsible	  for	  impaired	  responsiveness	  to	  erythropoiesis-­‐
stimulating	  agents	  and	  to	  growth	  hormone	  treatment	  [50–52].	  
	  
Surgical	  management	  of	  urolithiasis	  
(1)	   We	  do	  not	  recommend	  any	  kind	  of	  surgical	  intervention	  in	  PH1	  patients	  with	  uncomplicated	  urinary	  
stone	  disease,	  except	  when	  there	  is	  obstruction,	  infection	  or	  multiple	  urolithiasis.	  
(2)	   We	  recommend	  endoscopic	  procedure	  as	  preferential	  strategy	  to	  manage	  urolithiasis	  in	  patients	  who	  
require	  intervention.	  
The	  management	  of	  intraluminal	  stones	  by	  the	  urological	  surgeon	  is	  complicated	  by	  the	  potential	  of	  
concomitant	  presence	  of	  nephrocalcinosis.	  The	  successful	  removal	  of	  intraluminal	  stones	  can	  only	  be	  
assessed	  by	  endoscopy,	  as	  even	  successfully	  treated	  completely	  stone-­‐free	  kidneys	  will	  reveal	  ‘residual	  
stones’	  on	  imaging	  when	  nephrocalcinosis	  is	  present.	  Non-­‐endoscopic	  treatment	  (i.e.	  lithotripsy)	  holds	  the	  
risk	  of	  misinterpretation,	  which	  means	  that	  shock	  waves	  are	  applied	  on	  nephrocalcinosis	  spots	  instead	  of	  
stones	  [53].	  Different	  minimally	  invasive	  methods	  like	  extracorporeal	  shock	  wave	  lithotripsy	  (ESWL),	  semi-­‐
rigid	  ureterorenoscopy	  (URS),	  flexible	  ureterorenoscopy	  (RIRS),	  percutaneous	  nephrolithotomy	  (PCNL)	  and	  
laparoscopic	  approaches	  are	  currently	  established	  for	  interventional	  stone	  treatment.	  Open	  surgery	  has	  
become	  exceptional	  in	  this	  field.	  
ESWL	  has	  been	  successfully	  applied	  to	  most	  kidney	  and	  ureter	  stones	  and	  has	  emerged	  worldwide	  as	  a	  
standard	  tool	  [54].	  It	  is	  the	  preferred	  treatment	  for	  intrarenal	  calculi	  <20	  mm	  diameter.	  Success	  rates	  after	  
ESWL,	  meaning	  stone-­‐free	  kidneys,	  range	  from	  55	  to	  90%.	  However,	  ESWL	  means	  in	  situ	  fragmentation	  of	  
the	  stone,	  leaving	  the	  gravel	  behind	  for	  elimination	  by	  natural	  route.	  As	  a	  consequence,	  stone	  clearance	  of	  
the	  urinary	  tract	  can	  be	  incomplete.	  Up	  to	  60%	  of	  patients	  with	  small	  residual	  stone	  fragments	  (<3	  mm)	  
after	  ESWL	  will	  have	  increasing	  accumulation	  and	  formation	  of	  new	  stone	  masses	  on	  these	  residues	  [55].	  
PH1	  stone	  formers	  experience	  a	  high	  risk	  of	  prompt	  stone	  re-­‐growth	  on	  such	  residues	  because	  of	  ongoing	  
hyperoxaluria.	  
While	  guidelines	  still	  recommend	  ESWL	  [56],	  in	  daily	  practice,	  this	  is	  completely	  replaced	  by	  endoscopy	  in	  
PH1	  patients	  when	  multiple	  stones	  are	  present	  [57].	  URS,	  RIRS	  and	  PCNL	  allow	  fragmentation	  and	  achieve	  
removal	  of	  stone	  material	  under	  direct	  visual	  control.	  Stone	  size	  and	  localization	  determine	  whether	  a	  
retrograde,	  flexible	  or	  percutaneous	  access	  is	  the	  most	  appropriate	  technique.	  By	  the	  aid	  of	  pneumatic,	  
electrohydraulic,	  ultrasound	  or	  holmium	  laser	  probes,	  stones	  are	  crushed	  into	  small	  removable	  fragments	  
or	  even	  dust	  which	  can	  be	  flushed	  out.	  The	  patient	  can	  expect	  excellent	  stone-­‐free	  rates,	  reaching	  80–100%	  
for	  all	  techniques	  [URS,	  RIRS	  (kidney	  stones	  <	  20	  mm)	  and	  PCNL].	  Endoscopy	  allows	  a	  complete	  clearance	  of	  
the	  urinary	  tract	  at	  the	  end	  of	  the	  procedure,	  which	  is	  different	  from	  ESWL.	  
	  
Dialysis	  procedures	  
(1)	   We	  recommend	  avoiding	  any	  form	  of	  dialysis	  unless	  absolutely	  necessary	  and	  to	  consider	  pre-­‐emptive	  
transplantation	  in	  PH1	  patients	  with	  progressive	  CKD.	  
(2)	   We	  recommend	  using	  high	  efficacy	  dialysis,	  such	  as	  daily	  HD,	  nocturnal	  dialysis,	  combination	  of	  HD	  
and	  peritoneal	  dialysis	  (PD),	  in	  patients	  where	  pre-­‐emptive	  transplantation	  is	  not	  an	  option.	  
(3)	   We	  do	  not	  recommend	  dialysis	  in	  the	  early	  postoperative	  transplantation	  period	  other	  than	  
indications	  described	  in	  the	  transplant	  guidelines.	  
(4)	   We	  do	  recommend	  haemodialysis/filtration	  for	  clearance	  of	  oxalate	  during	  and	  after	  organ	  
transplantation	  in	  patients	  with	  systemic	  involvement	  and/or	  insufficient	  urine	  outflow	  in	  the	  early	  post-­‐
transplant	  period.	  
Although	  the	  molecular	  mass	  of	  oxalic	  acid	  is	  small	  (90	  Da),	  conventional	  dialysis	  is	  unable	  to	  remove	  
sufficient	  quantities	  of	  oxalate	  proportionate	  to	  the	  continuous	  daily	  production.	  Oxalate	  is	  generated	  at	  a	  
rate	  of	  4–7	  mmol/1.73m2	  per	  day	  in	  contrast	  to	  removal	  via	  conventional	  dialysis	  at	  a	  rate	  of	  1–2	  
mmol/1.73m2	  per	  day	  in	  adults	  and	  3–4	  mmol/1.73m2	  per	  day	  in	  children,	  resulting	  in	  an	  uncontrolled	  
tissue	  accretion	  rate	  [23,	  58,	  59].	  
Consequently,	  conventional	  dialysis	  is	  not	  considered	  ideal	  for	  patients	  with	  systemic	  oxalosis	  who	  have	  
reached	  ESRD	  [16,	  60].	  However,	  long-­‐term	  dialysis	  may	  be	  needed	  while	  awaiting	  organ	  transplantation	  
and	  achieving	  adequate	  body	  size.	  PD	  and	  HD	  have	  been	  used	  either	  alone	  or	  in	  combination	  in	  order	  to	  
maximize	  oxalate	  removal	  [59,	  61].	  The	  peculiar	  distribution	  of	  oxalate	  mass	  in	  the	  body	  explains	  the	  
limitations	  of	  dialysis	  treatment	  even	  when	  optimized.	  In	  systemic	  oxalosis,	  tissue	  oxalate	  is	  in	  equilibrium	  
with	  oxalate	  in	  body	  fluids.	  When	  plasma	  CaOx	  supersaturation	  (βCaOx)	  is	  reached,	  oxalate	  precipitation	  
occurs;	  the	  threshold	  of	  CaOx	  supersaturation	  (βCaOx	  >	  1)	  ranges	  between	  30	  and	  45	  μmol/L,	  also	  
depending	  on	  serum	  calcium	  concentration	  [62,	  63].	  Thus,	  the	  goal	  should	  be	  to	  lower	  POx	  enough	  with	  
dialysis	  to	  keep	  it	  below	  βCaOx	  for	  as	  long	  as	  possible	  during	  the	  interdialytic	  period.	  
Oxalate	  clearance	  on	  HD	  is	  greater	  than	  on	  PD	  (∼120	  mL/min	  on	  HD	  compared	  to	  ∼7	  mL/min	  on	  PD)	  [64].	  
Standard	  HD	  programmes	  will	  result	  in	  a	  weekly	  clearance	  of	  oxalate	  of	  6–9	  mmol/1.73m2	  per	  week	  
equivalent	  to	  2–3	  days	  of	  endogenous	  production	  of	  oxalate	  [65].	  PD	  is	  insufficient	  to	  clear	  adequate	  
quantities	  of	  oxalate	  but	  in	  some	  patients,	  a	  combination	  of	  overnight	  PD	  using	  continuous	  cycling	  
PD/nocturnal	  intermittent	  PD	  and	  intermittent	  daily	  HD	  can	  enhance	  the	  overall	  clearance	  of	  oxalate	  and	  
attempt	  to	  reduce	  the	  rebound	  which	  occurs	  after	  HD.	  The	  use	  of	  combination	  therapy,	  high-­‐flux	  dialysers	  
or	  long	  episodes	  of	  haemofiltration	  has	  been	  advocated	  to	  improve	  oxalate	  removal	  [60,	  66].	  
However,	  while	  HD	  can	  reduce	  POx	  by	  ∼60%	  following	  a	  dialysis	  session,	  this	  will	  return	  to	  80%	  of	  the	  pre-­‐
dialysis	  levels	  within	  24	  h	  as	  HD	  removes	  only	  a	  small	  fraction	  of	  total	  body	  oxalate,	  followed	  by	  a	  rebound	  
from	  bone	  turnover	  [67].	  
HD	  and/or	  continuous	  renal	  replacement	  therapy	  may	  be	  required	  following	  isolated	  liver	  transplantation	  
where	  sequential	  hepatorenal	  transplantation	  is	  being	  undertaken	  or	  following	  combined	  transplantation	  
where	  there	  has	  been	  a	  delay	  in	  improvement	  of	  renal	  graft	  function.	  In	  these	  circumstances,	  the	  benefit	  of	  
intra-­‐operative	  and	  post-­‐transplantation	  dialysis	  is	  debated.	  It	  can	  be	  considered	  in	  patients	  with	  significant	  
systemic	  involvement	  where	  the	  urine	  excretion	  is	  limited.	  Dialysis	  in	  these	  circumstances	  will	  produce	  a	  
rapid	  fall	  in	  POx	  thus	  protecting	  the	  transplanted	  kidney	  from	  tubulotoxic	  effects	  and	  oxalate	  deposition.	  In	  
any	  case,	  the	  risk	  of	  CaOx	  supersaturation	  should	  be	  avoided	  with	  accurate	  fluid	  management	  [60,	  68].	  
	  
Transplantation	  strategy	  
(1)	   We	  recommend	  planning	  pre-­‐emptive	  organ	  transplantation	  at	  CKD	  Stage	  3b	  to	  avoid	  the	  
complications	  of	  systemic	  oxalosis.	  
(2)	   We	  do	  not	  recommend	  isolated	  kidney	  transplantation,	  unless	  there	  is	  no	  other	  option.	  
(3)	   We	  recommend	  combined	  liver–kidney	  transplantation	  in	  most	  patients,	  either	  simultaneously	  or	  
sequentially	  according	  to	  patient's	  condition	  and	  to	  local	  facilities.	  
(4)	   We	  do	  not	  recommend	  pre-­‐emptive	  isolated	  liver	  transplantation	  unless	  in	  very	  well-­‐defined	  and	  
selected	  patients.	  
Organ	  transplantation	  should	  be	  planned	  prior	  to	  systemic	  oxalosis,	  i.e.	  before	  CKD	  Stage	  4.	  
Kidney	  transplantation	  
There	  is	  no	  scientific	  rationale	  for	  isolated	  kidney	  transplantation,	  and	  it	  should	  be	  considered	  only	  for	  
selected	  adult	  patients	  with	  confirmed	  evidence	  of	  B6	  responsiveness	  [38].	  
	  
Liver	  transplantation	  
As	  the	  liver	  is	  the	  only	  organ	  responsible	  for	  glyoxylate	  detoxification	  by	  AGT,	  the	  excessive	  production	  of	  
oxalate	  will	  continue	  as	  long	  as	  the	  native	  liver	  is	  left	  in	  place.	  
The	  strategy	  of	  liver–kidney	  transplantation	  is	  influenced	  by	  the	  stage	  of	  the	  disease	  (Table	  2)	  [69].	  
Simultaneous	  liver–kidney	  transplantation	  is	  logical	  in	  patients	  with	  CKD	  Stage	  4	  because,	  at	  this	  level,	  
oxalate	  retention	  increases	  rapidly.	  It	  has	  been	  used	  successfully	  with	  excellent	  outcome	  even	  in	  small	  
infants	  [70,	  71].	  A	  sequential	  procedure	  (first	  liver	  transplantation,	  followed	  by	  dialysis	  attempting	  to	  
reduce	  oxalate	  load	  from	  the	  body,	  with	  subsequent	  kidney	  transplantation)	  may	  be	  proposed	  in	  individual	  
ESRD	  patients.	  Pre-­‐emptive	  isolated	  liver	  transplantation	  may	  be	  an	  option	  in	  selected	  patients	  supervised	  
by	  a	  PH	  specialist	  [72–74].	  Such	  a	  strategy	  has	  a	  strong	  rationale	  but	  raises	  ethical	  controversies	  since	  the	  
transplant	  procedure	  of	  choice	  needs	  to	  be	  individualized	  as	  conservative	  management	  has	  improved	  long-­‐
term	  outcome	  in	  many	  patients	  with	  PH1.	  
Most	  publications	  currently	  report	  on	  the	  use	  of	  deceased	  donors	  but	  a	  living	  related	  donor	  for	  split	  liver	  or	  
renal	  donation	  may	  be	  considered	  under	  appropriate	  conditions.	  
	  
Post-­‐transplantation	  reversal	  of	  renal	  and	  extrarenal	  involvement	  
After	  combined	  liver–kidney	  transplantation,	  UOx	  can	  remain	  elevated	  for	  many	  years	  due	  to	  slow	  
resolubilization	  of	  systemic	  CaOx.	  Therefore,	  recurrent	  nephrocalcinosis	  or	  renal	  calculi	  is	  still	  a	  risk	  and	  
may	  jeopardize	  kidney	  graft	  function.	  The	  kidney	  must	  therefore	  be	  protected	  by	  forced	  fluid	  intake	  
supported	  by	  the	  use	  of	  crystallization	  inhibitors,	  and	  calcineurin	  inhibitors	  should	  be	  used	  with	  caution	  in	  
order	  to	  minimize	  additional	  nephrotoxicity.	  The	  benefit	  of	  post-­‐transplantation	  HD	  is	  still	  debated	  and	  
should	  be	  limited	  to	  patients	  with	  significant	  systemic	  involvement	  and	  those	  with	  acute	  tubular	  necrosis	  or	  
delayed	  graft	  function.	  
	  
Conclusions	  
Hyperoxaluria	  should	  be	  considered	  in	  any	  patient	  with	  a	  history	  of	  urolithiasis	  and/or	  nephrocalcinosis.	  
Such	  patients	  should	  be	  referred	  to	  reference	  centres	  with	  access	  to	  appropriate	  biochemical	  and	  
genotyping	  facilities.	  An	  early	  and	  accurate	  diagnosis	  leading	  to	  aggressive	  supportive	  treatment	  is	  a	  major	  
factor	  in	  short-­‐	  and	  long-­‐term	  outcomes.	  No	  method	  of	  dialysis	  is	  ideal;	  however,	  intensive	  extended	  daily	  
dialysis	  should	  be	  recommended.	  Early	  pre-­‐emptive	  transplantation	  should	  be	  considered	  in	  those	  with	  
impaired	  renal	  function	  at	  an	  early	  stage	  (CKD	  Stage	  3b);	  most	  experience	  in	  PH1	  is	  available	  with	  combined	  
liver–kidney	  transplantation.	  
New	  insights	  into	  potential	  therapies,	  including	  restoration	  of	  defective	  enzyme	  activity	  through	  chemical	  
chaperones,	  hepatocyte	  cell	  transplantation	  or	  recombinant	  gene	  therapy	  for	  enzyme	  replacement,	  
provide	  some	  hope	  for	  a	  curative	  approach	  of	  PH1	  in	  the	  future.	  
	  
Access	  to	  information	  
Several	  national	  and	  international	  societies	  provide	  information	  on	  the	  PHs.	  The	  Oxalosis	  and	  Hyperoxaluria	  
Foundation	  (www.ohf.org)	  has	  an	  extended	  website	  with	  open	  access	  and	  provides	  regular	  updates	  for	  
physicians,	  patients	  and	  scientists.	  It	  offers	  an	  overview	  of	  presentation,	  diagnosis	  and	  treatment	  of	  the	  
disease.	  The	  European	  Hyperoxaluria	  Consortium	  OxalEurope	  (www.oxaleurope.org)	  brings	  together	  
clinicians	  and	  scientists	  throughout	  Europe;	  it	  hosts	  a	  website	  that	  directs	  visitors	  to	  country	  and	  language-­‐
specific	  websites.	  UpToDate,	  Inc.	  (www.uptodate.com)	  and	  Medscape	  (www.medscape.com)	  provide	  
useful	  information.	  Genetic	  information	  can	  be	  obtained	  on	  www.orpha.net	  and	  www.genereviews.org.	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Organ	  involvement	  in	  PH	  patients	  with	  renal	  failurea	  
	  
Organ	   Symptoms	   Diagnosis	  




CT	  (cortical	  nephrocalcinosis	  may	  be	  missed	  
on	  US)	  
Bonec	   Fractures,	  bone	  pain,	  
growth	  retardation	  
X-­‐ray:	  dense	  or	  lucent	  metaphyseal	  bands	  at	  
the	  growth	  cartilage	  plate,	  vertebral	  
condensations,	  osteopenia,	  epiphyseal	  nuclei	  
(target-­‐like)	  knee	  epiphyses	  
Eyec	   Disturbed	  vision,	  specific	  
brown	  coloured	  retinal	  
deposits	  
Fundoscopy	  
Arteriesd	   Media	  calcifications	   US,	  CT	  
Myocardiumd	   Cardiac	  failure,	  arrhythmia,	  
heart	  block,	  left	  ventricular	  




Thyroidd	   Hypothyroidism	   US	  
Thyroid	  function	  tests	  





Nervese	   Ischaemic	  neuropathy	   Clinical	  assessment	  
Musclee	   Myopathy	  by	  CaOx	  
deposition	  
Biopsy,	  CT	  
Bowele	   Prolonged	  oxalosis:	  
depositions	  of	  CaOx	  in	  the	  
intestinal	  wall	  
CT	  
Jointse	   Arthritis	  (late	  sign)	   X-­‐ray,	  CT	  
↵a	  CT,	  computed	  tomography.	  
↵b	  Always	  involved.	  
↵c	  Frequently	  involved.	  
↵d	  Often	  involved.	  
↵e	  Less	  often	  involved.	  
Table	  2.	  
Suggested	  transplantation	  options	  in	  pyridoxine-­‐resistant	  PH1	  patients	  according	  to	  residual	  GFR,	  systemic	  
involvement	  and	  local	  facilitiesa	  
	  
Tx	  options	   Simultaneous	  
liver	  +	  kidney	  
Sequential	  liver–
kidney	  
Isolated	  kidney	   Isolated	  liver	  
HD	  strategy	   Peroperative	  ±	  
postoperative	  
according	  to	  POx	  
and	  GFR	  
Standard	  HD	  
following	  liver	  Tx	  






CKD	  Stage	  3	  
(30	  <	  GFR	  <	  
59)	  




CKD	  Stage	  4	  
(15	  <	  GFR	  <	  
29)	  
Yes	   Option	   Option	  if	  B6	  
response	  but	  no	  
evidence	  
No	  
CKD	  Stage	  5	  
(GFR	  <	  15)	  
Yes	   Yes	   Option	  if	  B6	  




(ESRD	  <	  2	  
years)	  
Yes	   Yes	   No	   No	  
a	  POx,	  plasma	  oxalate;	  Tx,	  transplantation.	  
